Quarterly report pursuant to Section 13 or 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.21.2
Significant Strategic Collaborations (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue $ 349,269 $ 115,934 $ 828,088 $ 285,610  
Research and development expenses 780,153 573,061 1,934,432 1,240,612  
Prepaid expenses and other current asset 878,243   878,243   $ 841,958
Takeda [Member] | Royalty Revenue [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 300,000 100,000 800,000 $ 300,000  
Serum Institute [Member] | Royalty Revenue [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 0 0      
Syn Bio [Member] | Royalty Revenue [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 0 0      
Pharmsynthez [Member] | Royalty Revenue [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 0 $ 0      
Scripps Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expenses     1,800,000    
Prepaid expenses and other current asset $ 200,000   $ 200,000   $ 200,000